Clinical trial results:
An open label, 52 week, multicenter study, of long term management to evaluate effectiveness, tolerability and safety of pimecrolimus cream 1%, Elidel® in pediatric patients with mild to moderate atopic dermatitis in a daily practice

Summary

EudraCT number	2017-001766-25
Trial protocol	Outside EU/EEA
Global end of trial date	18 September 2007

Results information

Result version number	v1 (current)
This version publication date	25 March 2018
First version publication date	25 March 2018

Trial information

Trial identification

Sponsor protocol code	CASM981CVE01

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00509990
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, +41 613241111,
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, +41 613241111,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 September 2007
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	18 September 2007
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the use of corticosteroid from day 1 to week 52 in patients using Elidel® cream 1% for the long term management in mild to moderate atopic dermatitis (AD) in pediatric patients in a daily practice.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	26 April 2005
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Mexico: 90
Country: Number of subjects enrolled	Venezuela, Bolivarian Republic of: 89
Worldwide total number of subjects	179
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	62
Children (2-11 years)	117
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	0

85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

A total of 179 children between 3 months and 12 year old, from a total of 10 centers located in Mexico and Venezuela, were enrolled.

Period 1

Period 1 title	Overall Period (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Arm title	Pimecrolimus cream 1 %

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Pimecrolimus cream 1 %
Investigational medicinal product code	
Other name	Elidel
Pharmaceutical forms	Cream
Routes of administration	Topical use

Dosage and administration details:

Elidel® b.i.d. on "as needed" basis to all affected areas.

Number of subjects in period 1	Pimecrolimus cream 1 %
Started	179
Completed	157
Not completed	22
Consent withdrawn by subject	7
Protocol violation	1
Unsatisfactory therapeutic effect	1
Lost to follow-up	12
Enrollment failure	1

Baseline characteristics

Reporting groups	
Reporting group title	Overall Period

Reporting group description: -

Reporting group values	Overall Period	Total	
Number of subjects	179	179	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	62	62	
Children (2-11 years)	117	117	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous Units: years			
arithmetic mean	4.13		
standard deviation	± 3.28	-	
Gender categorical Units: Subjects			
Female	96	96	
Male	83	83	

End points

End points reporting groups

Reporting group title	Pimecrolimus cream 1 %

Reporting group description: -

Primary: Total and relative number of patients distribution based on Corticosteroid use

End point title	Total and relative number of patients distribution based on Corticosteroid use[1]

End point description:

Corticosteroids use by patients during the course of the study.

End point type	Primary

End point timeframe:

up to week 52

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses have been reported for this primary end point.

End point values	Pimecrolimus cream 1 %			
Subject group type	Reporting group			
Number of subjects analysed	130[2]			
Units: patients				
number (not applicable)				
No	84			
Yes	46			

Notes:

[2] - Primary Endpoint population (per protocol)

Statistical analyses

No statistical analyses for this end point

Primary: Total and relative number of patients based on number of disease flares that required Corticosteroids treatment

End point title	Total and relative number of patients based on number of disease flares that required Corticosteroids treatment[3]

End point description:

End point type	Primary

End point timeframe:

up to week 52

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses have been reported for this primary end point.

End point values	Pimecrolimus cream 1 %			
Subject group type	Reporting group			
Number of subjects analysed	130[4]			
Units: patients				
number (not applicable)				
01	23			
02	10			
03	2			
04	3			
05	2			
More than 5	3			
Total	46			

Notes:

[4] - Primary Endpoint population (per protocol)

Statistical analyses

No statistical analyses for this end point

Primary: Duration of use of corticosteroids (non-continuous), within those patients that did use corticosteroids

End point title	Duration of use of corticosteroids (non-continuous), within those patients that did use corticosteroids[5]

End point description:

The average number of days Corticosteroids were used in the 52 week observation period.

End point type	Primary

End point timeframe:

up to week 52

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: No statistical analyses have been reported for this primary end point.

End point values	Pimecrolimus cream 1 %			
Subject group type	Reporting group			
Number of subjects analysed	179[6]			
Units: days				
number (not applicable)				
Less than a week	15			
1-2 weeks	12			
2-4 weeks	12			
More than a month	7			
Total	46			

Notes:

[6] - Primary Endpoint population (per protocol)

Statistical analyses

No statistical analyses for this end point

Secondary: Relative Patient distribution based on Investigator Global Assessment (IGA) per Visit

End point title	Relative Patient distribution based on Investigator Global Assessment (IGA) per Visit

End point description:

The evaluation of IGA indicates that the percentage of patients "without disease" and "almost without disease".

End point type	Secondary

End point timeframe:

up to week 52

End point values	Pimecrolimus cream 1 %			
Subject group type	Reporting group			
Number of subjects analysed	179[7]			
Units: percent				
number (not applicable)				
Visit 1 - No disease - Almost no disease	17.9			
Visit 1 - Mild disease - Severe Disease	82.1			
Visit 1 - Unknown	0			
Visit 1 - Total	100			
Visit 1 - Base	179			
Visit 2 - No disease - Almost no disease	69.5			
Visit 2 - Mild disease - Severe Disease	29.9			
Visit 2 - Unknown	0.6			
Visit 2 - Total	100			
Visit 2 - Base	174			
Visit 3 - No disease - Almost no disease	78.8			
Visit 3 - Mild disease - Severe Disease	21.12			
Visit 3 - Unknown	0			
Visit 3 - Total	100			
Visit 3 - Base	170			
Visit 4 - No disease - Almost no disease	82.9			
Visit 4 - Mild disease - Severe Disease	16.5			
Visit 4 - Unknown	0.6			
Visit 4 - Total	100			
Visit 4 - Base	164			
Visit 5 - No disease - Almost no disease	78.6			
Visit 5 - Mild disease - Severe Disease	21.4			
Visit 5 - Unknown	0			
Visit 5 - Total	100			
Visit 5 - Base	159			
Visit 6 - No disease - Almost no disease	80.9			
Visit 6 - Mild disease - Severe Disease	19.1			
Visit 6 - Unknown	0			
Visit 6 - Total	100			
Visit 6 - Base	157			

Notes:
[7] - per protocol population

Statistical analyses

No statistical analyses for this end point

Secondary: Relative Patient distribution based on Investigator Facial Global Assessment per Visit

End point title	Relative Patient distribution based on Investigator Facial Global Assessment per Visit

End point description:

End point type	Secondary

End point timeframe:
up to week 52

End point values	Pimecrolimus cream 1 %			
Subject group type	Reporting group			
Number of subjects analysed	179[8]			
Units: percent				
number (not applicable)				
Visit 1 - No disease - Almost no disease	63.1			
Visit 1 - Mild disease - Severe Disease	3639			
Visit 1 - Unknown	0			
Visit 1 - Total	100			
Visit 1 - Base	179			
Visit 2 - No disease - Almost no disease	90.8			
Visit 2 - Mild disease - Severe Disease	8.6			
Visit 2 - Unknown	0.6			
Visit 2 - Total	100			
Visit 2 - Base	174			
Visit 3 - No disease - Almost no disease	95.3			
Visit 3 - Mild disease - Severe Disease	4.7			
Visit 3 - Unknown	0			
Visit 3 - Total	100			
Visit 3 - Base	170			
Visit 4 - No disease - Almost no disease	93.9			
Visit 4 - Mild disease - Severe Disease	6.1			
Visit 4 - Unknown	0.6			
Visit 4 - Total	100			
Visit 4 - Base	164			
Visit 5 - No disease - Almost no disease	93.1			
Visit 5 - Mild disease - Severe Disease	6.3			
Visit 5 - Unknown	0.6			

Visit 5 - Total	100			
Visit 5 - Base	159			
Visit 6 - No disease - Almost no disease	96.2			
Visit 6 - Mild disease - Severe Disease	3.8			
Visit 6 - Unknown	0			
Visit 6 - Total	100			
Visit 6 - Base	157			

Notes:

[8] - per protocol population

Statistical analyses

No statistical analyses for this end point

Secondary: Average Scores for Parent Index Quality of Life questionnare per Visit

End point title	Average Scores for Parent Index Quality of Life questionnare per Visit

End point description:

End point type	Secondary

End point timeframe:

up to week 52

End point values	Pimecrolimus cream 1 %			
Subject group type	Reporting group			
Number of subjects analysed	179[9]			
Units: scores on a scale				
number (not applicable)				
Visit 1	12.32			
Visit 4	8.82			
Visit 6	7.22			

Notes:

[9] - per protocol population
n = 148, 156, 140

Statistical analyses

No statistical analyses for this end point

Secondary: Average Scores for Child Index Quality of Life questionnaire per Visit

End point title	Average Scores for Child Index Quality of Life questionnaire per Visit

End point description:

End point type	Secondary

End point timeframe:

up to week 52

End point values	Pimecrolimus cream 1 %			
Subject group type	Reporting group			
Number of subjects analysed	179[10]			
Units: scores on a scale				
number (not applicable)				
Visit 1	7.9			
Visit 2	4.4			
Visit 3	3.9			
Visit 4	2.7			
Visit 5	2.4			
Visit 6	2.2			

Notes:

[10] - per protocol population
n= 53, 54, 59, 62, 52, 53

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.

Assessment type	Systematic

Dictionary used

Dictionary name	Unspecified
Dictionary version	unk

Reporting groups

Reporting group title	Pimecrolimus cream 1 %

Reporting group description: -

Serious adverse events	Pimecrolimus cream 1 %		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 179 (1.68%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Gastrointestinal disorders			
Diarrhea and gastroenteritis of presumed infectious origin			
subjects affected / exposed	1 / 179 (0.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cellulitis, unspecified			
subjects affected / exposed	1 / 179 (0.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia, unspecified			
subjects affected / exposed	1 / 179 (0.56%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Pimecrolimus cream 1 %		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	135 / 179 (75.42%)		
Gastrointestinal disorders			
Diarrhoea infectious			
subjects affected / exposed	44 / 179 (24.58%)		
occurrences (all)	44		
Respiratory, thoracic and mediastinal disorders			
Acute Upper Respiratory Tract Infection			
subjects affected / exposed	134 / 179 (74.86%)		
occurrences (all)	134		
Allergic Rhinitis			
subjects affected / exposed	71 / 179 (39.66%)		
occurrences (all)	71		
Cough			
subjects affected / exposed	59 / 179 (32.96%)		
occurrences (all)	59		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported